Core Viewpoint - The chairman of New Mileage, Lin Yanglin, is under investigation by the Taiyuan Municipal Xiaodian District Supervisory Committee, which has led to his inability to perform his duties. The company stated that the matter is unrelated to its operations and has not been asked to assist in the investigation [1]. Group 1: Company Operations - New Mileage's main business segments include medical services and traditional Chinese medicine, with medical services accounting for approximately 80% of its revenue [2]. - In 2024, New Mileage reported a revenue of 3.799 billion yuan and a net profit attributable to shareholders of 115 million yuan [1]. - The company operates six regional medical centers across various provinces and has a total of 24 hospitals, including three tertiary hospitals and 14 secondary or higher-level hospitals [2]. Group 2: Corporate Structure and History - New Mileage's pharmaceutical business is primarily centered around the "Duyiwei" brand of traditional Chinese medicine, which contributes about 20% to its revenue [4]. - The company was formerly known as Hengkang Medical and became controlled by Beijing New Mileage Health Industry Group in 2022 [4]. - New Mileage Group manages over 40 hospitals across nearly 20 provinces, with a total bed capacity of 30,000, ranking among the top three in the country [4]. Group 3: Financial and Regulatory Issues - On June 20, Lin Yanglin and the CFO Liu Jun were subjected to regulatory discussions by the Gansu Securities Regulatory Bureau due to non-compliance with accounting standards related to stock incentive plans and construction project accounting [6]. - The financial discrepancies have led to inaccurate disclosures in the consolidated balance sheets for the fiscal years 2023 and the first three quarters of 2024, violating the regulations on information disclosure for listed companies [6].

Group 1: Management Changes in the Alcohol Industry - The alcohol industry has seen a series of high-level management changes since last year, with companies like Yanghe, China Resources Beer, and Jinzhongzi Wine experiencing shifts in leadership, indicating a strong intent from shareholders and investors to boost performance [1] - Jinzhongzi Wine's General Manager He Xiuxia has resigned, and the company is facing significant market share pressure, with 2024 revenue projected to drop to 925 million yuan, a stark contrast to over 2 billion yuan in previous cycles [5] - Yanghe has appointed Gu Yu as the new Party Secretary, replacing Zhang Liandong, who has stepped down amid a challenging period for the white liquor industry [6][7] Group 2: Trade and Regulatory Developments - The Ministry of Commerce has concluded an anti-dumping investigation into EU brandy, determining that dumping margins range from 27.7% to 34.9%, leading to the imposition of anti-dumping duties starting July 5, 2025 [2][3] - A total of 34 EU brandy exporters, including well-known brands like Martell and Hennessy, can avoid these duties by adhering to price commitments approved by Chinese authorities [3] Group 3: Market Trends and Promotions - Taobao Flash Sale has initiated a new subsidy program, investing 50 billion yuan, resulting in a significant increase in orders, particularly in the alcohol sector, with some brands seeing order volumes double [4] - Kuaizi Jiao reported that its high-end "Jian" series products have not performed as expected, with sales and consumer feedback being less favorable compared to older products [10] - Xijiu has launched a promotional campaign offering buy-three-get-one-free deals on various products, indicating a strategy to boost sales through consumer incentives [11]

Core Viewpoint - The announcement details the completion of the initial registration for the 2025 Restricted Stock Incentive Plan by Shanghai NAR Industrial Co., Ltd, highlighting the approval processes, stock allocation, and performance assessment criteria for the incentive plan [1][2][3]. Summary by Sections Approval Process - The 2025 Restricted Stock Incentive Plan has undergone necessary approval procedures, including the review and consent from the Compensation and Assessment Committee of the Board [1][2]. - No objections were raised during the public notice period by the Supervisory Board [1]. Initial Grant of Restricted Stock - A total of 91.706 million shares were granted to 37 core personnel, representing 19.74% of the incentive plan and 0.27% of the total share capital on the announcement date [2][3]. - The effective period of the incentive plan is up to 48 months from the date of the initial grant [2]. Lock-up Period and Release Schedule - The lock-up periods for the granted restricted stocks are set at 12, 24, and 36 months, with specific release percentages of 35% for the first two periods and 30% for the last [3][4]. Performance Assessment Criteria - The performance assessment for the incentive plan will be based on the company's total revenue and net profit for the fiscal years 2025-2027, with specific targets set for each assessment year [5][6]. - The performance targets are equally weighted, with a 50% contribution from both revenue and profit metrics [6]. Financial Impact and Fund Utilization - The funds raised from the stock grants will be used to supplement the company's working capital [8]. - The issuance of restricted stocks will have an impact on the company's financial status, with specific amortization costs outlined for the years 2025 to 2028 [8][9]. Stock Structure Changes - Following the completion of the grant registration, the total number of shares increased to 341,535,127, with no change in the control of the company or its compliance with listing conditions [7][8].

截至2025年7月4日收盘，天臣医疗（688013）报收于29.99元，较上周的27.31元上涨9.81%。本周，天 臣医疗7月4日盘中最高价报31.96元，股价触及近一年最高点。6月30日盘中最低价报27.47元。天臣医疗 当前最新总市值24.34亿元，在医疗器械板块市值排名115/126，在两市A股市值排名4712/5149。 公司于2025年7月3日完成2023年限制性股票激励计划第二个归属期的股份登记工作。本次归属股票数量 为556,000股，来源于公司从二级市场回购的A股普通股股票，归属人数为89人。公司实际收到89名激励 对象缴纳的资本总额共计人民币5,977,000.00元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 天臣国际医疗科技股份有限公司于2023年12月27日开始实施股份回购计划，回购资金总额逐步调整为不 低于4600万元，不超过8000万元，回购期限延长至2025年12月26日。截至2025年6月30日，公司已累计 回购股份2505324股，占公司总股本的3.09%，支付的资金总额约为4249.89万 ...

欢迎扫描下方二维码关注： 企业所得税汇算清缴中，工资薪金是常见的税前扣除事项，也是纳税人咨询的高频、热点问题。由于有时对政策理解不够 准确，纳税人汇算清缴申报时容易发生错误扣除的情形。那么，工资薪金应该如何进行企业所得税税前扣除呢？我们一起来看 看吧～ 一、 工资薪金税前扣除的范围是什么？ 答：根据《中华人民共和国企业所得税法实施条例》第三十四条的规定，企业发生的合理的工资薪金支出，准予扣除。 工资薪金，是指企业每一纳税年度 支付给 在本企业任职或者受雇的员工的所有现金形式或者非现金形式的劳动报酬，包括基本工 资、奖金、津贴、补贴、年终加薪、加班工资，以及与员工任职或者受雇有关的其他支出。 二、 什么是"合理的"工资薪金？ 答：根据《国家税务总局关于企业工资薪金及职工福利费扣除问题的通知》 （国税函〔2009〕3号） 第一条的规定，"合理工资薪 金"是指企业按照股东大会、董事会、薪酬委员会或相关管理机构制订的工资薪金制度规定实际发放给员工的工资薪金。 在对工资薪金进行合理性确认时，可按 以下原则 掌握： 三、 计算职工福利费、教育经费、工会经费扣除限额时的"工资薪金总额"是什么？ 答：应 区分为工资薪金支出和 ...

广州万孚生物技术股份有限公司董事会 公司债权人如要求公司清偿债务或提供相应担保的，应根据《中华人民共和国公司法》等相关法律法规 的规定，向公司提出书面要求，并附随有关证明文件。如债权人未在规定期限内行使上述权利的，公司 本次回购注销限制性股票将按法定程序继续实施。 特此公告。 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈述或者重大遗漏。 2025年7月4日，广州万孚生物技术股份有限公司（以下简称"公司"）召开2025年第一次临时股东大会， 审议通过了《关于终止实施 2024 年限制性股票激励计划暨回购注销限制性股票的议案》，因公司经营 所面临的内外部环境与制定股权激励计划时相比发生了较大变化，导致公司预期经营情况与激励方案考 核指标的设定存在偏差，继续推进和实施激励计划难以达到对激励对象的激励效果。经公司董事会审慎 考虑后，决定终止实施 2024 年限制性股票激励计划，并回购注销公司 2024 年限制性股票激励计划所涉 及的已授予但尚未解除限售的限制性股票 1054.40 万股，同时与之配套的《2024 年限制性股票激励计划 实施考核管理办法》等相关文件一并终止。具体内容详见公司 ...

浙江水晶光电科技股份有限公司 2025 年限制性股票激励计划（草案）摘要 证券简称：水晶光电 证券代码：002273 公告编号：（2025）036 号 浙江水晶光电科技股份有限公司 二〇二五年七月 浙江水晶光电科技股份有限公司 2025 年限制性股票激励计划（草案）摘要 声明 本公司及董事会、监事会全体成员保证本激励计划及其摘要内容的真实、准 确和完整，没有虚假记载、误导性陈述或重大遗漏。 浙江水晶光电科技股份有限公司 2025 年限制性股票激励计划（草案）摘要 特别提示 《浙江水晶光电科技股份有限公司 2025 年限制性股票激励计划（草案）》 由浙江水晶光电科技股份有限公司（以下简称"水晶光电""公司"或"本公司"） 依据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股权激励 管理办法》《深圳证券交易所上市公司自律监管指南第 1 号——业务办理》和其 他有关法律、行政法规、规范性文件，以及《公司章程》等有关规定制订。 二、水晶光电 2025 年限制性股票激励计划（以下简称"本激励计划"）采取 的激励形式为限制性股票。股票来源为公司从二级市场回购的本公司人民币 A 股 普通股股票。 符合本激励计划 ...

浙江水晶光电科技股份有限公司 是否存在 序 该事项（是 号 事项 备注 /否/不适 用） 上市公司合规性要求 股权激励计划自查表 公司简称：水晶光电 股票代码：002273 独立财务顾问：无 激励对象为董事、高管的，是否设立绩效考核指标 作为激励对象行使权益的条件 最近一个会计年度财务会计报告是否未被注册会计 师出具否定意见或者无法表示意见的审计报告 最近一个会计年度财务报告内部控制是否未被注册 会计师出具否定意见或无法表示意见的审计报告 上市后最近36个月内是否未出现过未按法律法规、 公司章程、公开承诺进行利润分配的情形 是否未为激励对象提供贷款以及其他任何形式的财 务资助 激励对象合规性要求 是否未包括单独或合计持有上市公司5%以上股份的 股东或实际控制人及其配偶、父母、子女 是否最近12个月内未被证券交易所认定为不适当人 选 是否最近12个月内未被中国证监会及其派出机构认 定为不适当人选 是否最近12个月内未因重大违法违规行为被中国证 监会及其派出机构行政处罚或者采取市场禁入措施 是否不存在《公司法》规定的不得担任公司董事、 高级管理人员情形 激励计划合规性要求 上市公司全部在有效期内的股权激励计划所涉 ...

证券代码：000876 证券简称：新希望 公告编号：2025-60 债券代码：127015，127049 债券简称：希望转债，希望转 2 新希望六和股份有限公司 关于 2022 年度限制性股票激励计划 回购注销限制性股票完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 共涉及 526 名激励对象，合计 2,337.22 万股，占回购前公司总股本的 0.52%。 理完成了上述限制性股票的回购注销手续。本次回购注销完成后，公司总股本由 公司于 2023 年 7 月 25 日召开了第九届董事会第十六次会议和第 九届监事会第十二次会议，并于 2023 年 10 月 27 日召开 2023 年第二 次临时股东大会审议通过了《关于回购注销部分限制性股票的议案》 同意公司回购注销 2022 年限制性股票激励计划(以下简称"2022 年 激励计划"）55 名激励对象所持有的未解除限售的合计 463.2 万股限 制性股票。 公司于 2023 年 10 月 27 日召开第九届董事会第二十次会议及第 九届监事会第十五次会议，并于 2025 年 4 月 3 日召 ...

Core Viewpoint - The legal opinion letter confirms that Shenzhen Xianying Technology Co., Ltd. is eligible to implement its 2025 restricted stock incentive plan, adhering to relevant laws and regulations [4][21][26]. Group 1: Company Overview - Shenzhen Xianying Technology Co., Ltd. was established as a joint-stock company through the overall change of Shenzhen Xianying Electronic Technology Co., Ltd. [5]. - The company is listed on the Shenzhen Stock Exchange with the stock code 301067 and has a unified social credit code of 91440300578820507D [6][7]. Group 2: Incentive Plan Details - The 2025 restricted stock incentive plan was approved by the company's board of directors on July 3, 2025, and includes provisions for the management of the incentive plan [8][21]. - The plan aims to establish a long-term incentive mechanism to attract and retain talent, aligning the interests of shareholders, the company, and employees [9][26]. Group 3: Eligibility and Scope of Incentive Objects - The incentive objects include 29 individuals, such as directors, senior management, and core technical personnel, excluding independent directors and major shareholders [11][23]. - The plan includes one foreign employee, MAO DAN YUN, who plays a significant role in the company's R&D efforts [12]. Group 4: Stock Allocation and Conditions - The plan proposes to grant 890,400 restricted stocks, accounting for approximately 0.92% of the company's total share capital [17]. - The allocation of restricted stocks is detailed, ensuring compliance with regulations regarding the distribution among incentive objects [15][17]. Group 5: Legal Compliance and Procedures - The plan has undergone necessary legal procedures, including board approval and public disclosure requirements, ensuring compliance with the Company Law and Securities Law [21][22]. - The company has committed not to provide financial assistance to incentive objects for acquiring restricted stocks, aligning with regulatory requirements [26].